nach oben

Erschienen in:

2016 | OriginalPaper | Buchkapitel

3. Alternative Verfahren bei Urothelkarzinom

verfasst von : Priv.-Doz. Dr. med. C. Kempkensteffen, Prof. Dr. med. K. Miller, Prof. Dr. med. S. Höcht, Dr. med. M. Nausner, Priv.-Doz. Dr. med. F. Christoph

Erschienen in: Alternative operative Therapien in der Uroonkologie

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Prognose des Urothelkarzinoms der Harnblase wird im Wesentlichen geprägt von den Kriterien Infiltrationstiefe und Differenzierungsgrad im Tumor. Um das Rezidiv- und Progressionsrisiko so gering wie möglich zu halten, werden nach transurethraler Blasentumorresektion (TUR-B) adjuvante Konzepte der Blaseninstillationstherapie angewandt (Mitomycin C und Bacillus-Calmette-Guérin). Möglicherweise kann das Rezidivrisiko durch den Einsatz der Hyperthermie in Verbindung mit Mitomycin weiter gesenkt werden. Für Patienten, die aus Altersgründen, aufgrund von Komorbiditäten oder einfach auch wegen des Wunsches nach Organerhalt eine Zystektomie beim muskelinvasiven Harnblasentumor ablehnen, besteht die Möglichkeit einer kombinierten Radiochemotherapie. Grundvoraussetzung ist eine geringe Resttumorlast nach TUR-B. Blasenteilresektionen bleiben nur streng selektionierten Patientengruppen mit guter Blasenkapazität, unifokalen Tumoren und einer hohen Compliance vorbehalten.

Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol 48(2):202-205; discussion 205–206

Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, Sylvester RJ, Kaasinen E, Bohle A, Palou Redorta J, Roupret M, European Association of Urology (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64(4):639–653CrossRefPubMed

Barentsz JO, Jager GJ, Witjes JA, Ruijs JH (1996) Primary staging of urinary bladder carcinoma: the role of MRI and a comparison with CT. Eur Radiol 6(2):129–133CrossRefPubMed

Berrum-Svennung I, Granfors T, Jahnson S, Boman H, Holmang S (2008) A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol 179(1):101-105; discussion 105–106CrossRef

Bohle A, Bock PR (2004) Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63(4):682-686; discussion 686–687CrossRef

Bostrom PJ, Kossi J, Laato M, Nurmi M (2009) Risk factors for mortality and morbidity related to radical cystectomy. BJU Int 103(2):191–196CrossRefPubMed

Braendengen M, Winderen M, Fossa SD (1996) Clinical significance of routine pre-cystectomy bone scans in patients with muscle-invasive bladder cancer. Br J Urol 77(1):36–40CrossRefPubMed

Capitanio U, Isbarn H, Shariat SF, Jeldres C, Zini L, Saad F, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI (2009) Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysist. Urology 74(4):858–864CrossRefPubMed

Chung PW, Bristow RG, Milosevic MF, Yi QL, Jewett MA, Warde PR, Catton CN, McLean M, Moore M, Tannock IF, Gospodarowicz MK (2007) Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol 25(4):303–309CrossRefPubMed

Dandekar NP, Tongaonkar HB, Dalal AV, Kulkarni JN, Kamat MR (1995) Partial cystectomy for invasive bladder cancer. J Surg Oncol 60(1):24–29CrossRefPubMed

Donat SM (2006) Staged based directed surveillance of invasive bladder cancer following radical cystectomy: valuable and effective? World J Urol 24(5):557–564CrossRefPubMed

Froehner M, Brausi MA, Herr HW, Muto G, Studer UE (2009) Complications following radical cystectomy for bladder cancer in the elderly. Eur Urol 56(3):443–454CrossRefPubMed

Gudjonsson S, Adell L, Merdasa F, Olsson R, Larsson B, Davidsson T, Richthoff J, Hagberg G, Grabe M, Bendahl PO, Mansson W, Liedberg F (2009) Should all patients with non-muscle-invasive bladder cancer receive early intra-vesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 55(4):773–780CrossRefPubMed

Han RF, Pan JG (2006) Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 67(6):1216–1223CrossRefPubMed

Herr HW, Bajorin DF, Scher HI (1998) Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 16(4):1298–1301PubMed

Hollenbeck BK, Taub DA, Dunn RL, Wei JT (2005) Quality of care: partial cystectomy for bladder cancer - a case of inappropriate use? J Urol 174(3):1050-1054; discussion 1054CrossRefPubMed

Holzbeierlein JM, Lopez-Corona E, Bochner BH, Herr HW, Donat SM, Russo P, Dalbagni G, P Sogani C (2004) Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol 172(3):878–881CrossRefPubMed

Huguet J (2013) Follow-up after radical cystectomy based on patterns of tumour recurrence and its risk factors. Actas Urol Esp 37(6):376–382CrossRefPubMed

International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, Club Urologico Espanol de Tratamiento Oncologico Group, Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29(16):2171–2177CrossRefPubMedCentral

Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke A, Munsell MF, Grossman HB, Dinney CP (2006) Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the Anderson Cancer Center experience. J Urol 175(6):2058–2062CrossRefPubMed

Khaled HM, Shafik HE, Zabhloul MS, Ghoneim M, Saber RA, Manie M, Enein HA, Megeed HA, Mansur O, Sherbini ME, Mahran TZ, Kalawee ME, Badran A, Ramadan SM (2014) Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation. Clin Genitourin Cancer 12(5):e233–240CrossRef

Kim DK, Lee JW, Park SY, Kim YT, Park HY, Lee TY (2010) Initial experience with robotic-assisted laparoscopic partial cystectomy in urachal diseases. Korean J Urol 51(5): 318–322CrossRefPubMedPubMedCentral

Knoedler JJ, Boorjian SA, Kim SP, Weight CJ, Thapa P, Tarrell RF, Cheville JC, Frank I (2012) Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis. J Urol 188(4):1115–1119CrossRefPubMed

Lei Y, Tong S, Zu X, Li Y, He W, Hu X, Liu W, Wang Z, Qi L, Chen M (2015) Extraperitoneal and transperitoneal laparoscopic partial cystectomy for benign non-urothelial bladder tumors: an initial experience. Urol Int 94(2):149–155CrossRefPubMed

Leibovici D, Kassouf W, Pisters LL, Pettaway CA, Wu X, Dinney CP, Grossman HB (2007) Organ preservation for muscle-invasive bladder cancer by transurethral resection. Urology 70(3):473–476CrossRefPubMed

Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, Cote RJ, Urun Y, Chang SL, Choueiri TK, Bellmunt J (2014) Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol 66(1): 42–54CrossRefPubMed

Peress JA, Waterhouse K, Cole AT (1977) Complications of partial cystectomy in patients with high grade bladder carcinoma. J Urol 118(5):761PubMed

Picozzi S, Ricci C, Gaeta M, Ratti D, Macchi A, Casellato S, Bozzini G, Carmignani L (2012) Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13185 patients. J Urol 188(6): 2046–2054

Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rodel CM, Shariat SF, Shipley WU, Sternberg CN, Thalmann GN, Kassouf W (2014) Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol 66(1): 120–137CrossRefPubMed

Rosenblatt R, Sherif A, Rintala E, Wahlqvist R, Ullen A, Nilsson S, Malmstrom PU, Nordic Urothelial Cancer Group (2012) Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol 61(6):1229–1238CrossRef

Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD (2004) Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 93(4):485–490CrossRefPubMed

Simone G, Papalia R, Ferriero M, Guaglianone S, Castelli E, Collura D, Muto G, Gallucci M (2013) Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy. Int J Urol 20(4):390–397CrossRefPubMed

Smaldone MC, Jacobs BL, Smaldone AM, Hrebinko RL Jr (2008) Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma. Urology 72(3): 613–616CrossRefPubMed

Solsona E, Iborra I, Collado A, Rubio-Briones J, Casanova J, Calatrava A (2010) Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol 184(2):475–80CrossRefPubMed

Soukup V, Babjuk M, Bellmunt J, Dalbagni G, Giannarini G, Hakenberg OW, Herr H, Lechevallier E, Ribal MJ (2012) Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. Eur Urol 62(2):290–302CrossRefPubMed

Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 19(3):666–675PubMed

Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA, European Association of Urology (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 59(6):1009–1018CrossRefPubMed

Svatek RS, Shariat SF, Lasky RE, Skinner EC, Novara G, Lerner SP, Fradet Y, Bastian PJ, Kassouf W, Karakiewicz PI, Fritsche HM, Muller SC, Izawa JI, Ficarra V, Sagalowsky AI, Schoenberg MP, Siefker-Radtke AO, Millikan RE, Dinney CP (2010) The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res 16(17):4461–467CrossRefPubMed

Sweeney P, Kursh ED, Resnick MI (1992) Partial cystectomy. Urol Clin North Am 19(4):701-711

van der Sylvester RJ, van der Meijden AP, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168(5):1964–1970

Vazina A, Dugi D, Shariat SF, Evans J, Link R, Lerner SP (2004) Stage specific lymph node metastasis mapping in radical cystectomy specimens. J Urol 171(5):1830–1834CrossRefPubMed

Baumann BC, Guzzo TJ, He J, Vaughn DJ, Keefe SM, Vapiwala N, Deville C, Bekelman JE, Tucker K, Hwang WT, Malkowicz SB, Christodouleas JP (2013) Bladder cancer patterns of pelvic failure: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 85:363–369CrossRefPubMed

Bellmunt J, Orsola A, Wiegel T, Guix M, De Santis M, Kataja V, ESMO Guidelines Working Group (2011) Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi45–49

Chauvet B, Brewer Y, Felix-Faure C, Davin JL, Choquenet C, Reboul F (1996) Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy. J Urol 156:1258–1262CrossRefPubMed

Chauvet B, Felix-Faure C, Davin JL, Choquenet C, Alfonsi M, Reboul F (1998) Results of long-term treatment of inoperable cancer of the bladder with cisplatin and concurrent irradiation: prognostic factors of local control and survival. Cancer Radiother 2(Suppl 1): 85s-91s

Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, Pater J, Sullivan LD for the National Cancer Institute Trialist Group (1996) Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J Clin Oncol 14:2901–2907PubMed

Dees-Ribbers HM, Pos FJ, Betgen A, Bex A, Hulshof MC, Remeijer P, van Herk M (2013) Fusion of planning CT and cystoscopy images for bladder tumor delineation: a feasibility study. Med Phys 40:05171–3CrossRef

Dunst J, Diestelhorst A, Kühn R, Müller AC, Scholz HJ, Fornara P (2005) Organ-sparing treatment in muscle-invasive bladder cancer. Strahlenther Onkol 181:632–637CrossRefPubMed

Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, Sandler HM (2009) Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 27:4055–4061CrossRefPubMedPubMedCentral

Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, Coen JJ, Skowronski RY, Paly JJ, McGovern FJ, Zietman AL (2012) Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 61:705–711CrossRefPubMed

Hoskin PJ, Rojas AM, Saunders MI, Bentzen SM, Motohashi KJ, BCON investigators (2009) Carbogen and nicotinamide in locally advanced bladder cancer: early results of a phase-III randomized trial. Radiother Oncol 91:120–125CrossRefPubMed

Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI (2010) Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 28:4912–4918CrossRefPubMed

Housset M, Maulard C, Chretien Y, Dufour B, Delanian S, Huart J, Colardelle F, Brunel P, Baillet F (1993) Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 2150–2157

Huddart RA, Hall E, Hussain SA, Jenkins P, Rawlings C, Tremlett J, Crundwell M, Adab FA, Sheehan D, Syndikus I, Hendron C, Lewis R, Waters R, James ND (2013) Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscleinvasive bladder cancer: results of the BC2001 trial (CRUK/01/004). Int J Radiat Oncol Biol Phys 87:261–269CrossRefPubMedPubMedCentral

James ND, Hussain SA (2013) A multidisciplinary approach in muscle-invasive disease: novel chemotherapy combinations and targets in chemoradiation. Am Soc Clin Oncol Educ Book 33:200–206CrossRef

James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Sizer B, Sreenivasan T, Hendron C, Lewis R, Waters R, Huddart RA, BC2001 Investigators (2012) Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 366:1477–1488

Jentzmik F, Schostak M, Stephan C, Baumunk D, Lingnau A, Weikert S, Lein M, Miller K, Schrader M (2010) Extraperitoneal radical cystectomy with extraperitonealization of the ileal neobladder: a comparison to the transperitoneal technique. World J Urol 28:457–463CrossRefPubMed

Keck B, Ott OJ, Häberle L, Kunath F, Weiss C, Rödel C, Sauer R, Fietkau R, Wullich B, Krause FS (2013) Female sex is an independent risk factor for reduced overall survival in bladder cancer patients treated by transurethral resection and radio- or radiochemotherapy. World J Urol 31:1023–1028CrossRefPubMed

Krause FS, Walter B, Ott OJ, Häberle L, Weiss C, Rödel C, Wullich B, Sauer R (2011) 15-year survival rates after transurethral resection and radiochemo-therapy or radiation in bladder cancer treatment. Anticancer Res 31:985–990PubMed

Meijer GJ, van der Toorn PP, Bal M, Schuring D, Weterings J, de Wildt M (2012) High precision bladder cancer irradiation by integrating a library planning procedure of 6 prospectively generated SIB IMRT plans with image guidance using lipiodol markers. Radiother Oncol 105:174–179CrossRefPubMed

Milosevic M, Gospodarowicz M, Zietman A, Abbas F, Haustermans K, Moonen L, Rödel C, Schoenberg M, Shipley W (2007) Radiotherapy for bladder cancer. Urology 69 (Suppl 1):80–92CrossRefPubMed

Mitin T, George A, Zietman AL, Kaufman DS, Uzzo RG, Dreicer R, Heney NM, Wallace HJ, Souhami L, Dobelbower MC, Sandler HM, Shipley WU (2014) Long-term outcomes among patients who achieve complete or near-complete responses after the induction phase of bladder-preserving combined modality therapy for muscle-invasive bladder cancer: a pooled analysis of RTOG 9906 and 0233. J Clin Oncol 32(Suppl 4):28–4

Munro NP, Sundaram SK, Weston PM, Fairley L, Harrison SC, Forman D, Chahal R (2010) A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK. Int J Radiat Oncol Biol Phys 77:119–124CrossRefPubMed

Nishioka K, Shimizu S, Shinohara N, Ito YM, Abe T, Maruyama S, Kinoshita R, Harada K, Nishikawa N, Miyamoto N, Onimaru R, Shirato H (2014) Prospective phase II study of image-guided local boost using a Real-time Tumortracking Radiotherapy (RTRT) system for locally advanced bladder cancer. Jpn J Clin Oncol 44:28–35CrossRefPubMed

Nieuwenhuijzen JA, de Vries RR, Bex A, van der Poel HG, Meinhardt W, Antonini N, Horenblas S (2008) Urinary diversion after cystectomy: the association of clinical factors, complications and functional results of four different diversions. Eur Urol 53:834–844CrossRefPubMed

Rödel C, Grabenbauer GG, Kühn R, Papadopoulos T, Dunst J, Meyer M, Schrott KM, Sauer R (2002) Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20: 3061–3071CrossRefPubMed

Rödel C, Weiss C, Sauer R (2006) Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 24:5536–5544CrossRefPubMed

Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, Raj G, Bochner BH, Dalbagni G, Herr HW, Donat SM (2009) Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 55:164–176CrossRefPubMed

Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Sherif A (2013) EAU-guidelines on muscle-invasive and metastatic bladder cancer (update March 2013). http://www.uroweb.org/gls/pdf/07_Bladder%20CancerLR.pdf . Zugegriffen: 1. Januar 2014

Zapatero A, Martin de Vidales C, Arellano R, Bocardo G, Perez M, Rfos P (2010) Updated results of bladder-sparing trimodality approach for invasive bladder cancer. Urol Oncol 28:368–374CrossRefPubMed

Ayres B, Connor A, Corbishley C, Bailey MJ (2010) 3-year single centre UK experience of radiofrequency hyperthermia and Mitomycin C in BCG failures. (Posterpräsentation im Rahmen des BAUS-Jahrestreffens am 23.06.2010 in Manchester, UK)

Colombo R, Lev A, Da Pozzo LF, Freschi M, Gallus G, Rigatti P (1995) A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment. J Urol 153(3 Pt 2):959–963PubMed

Colombo R, Da Pozzo LF, Lev A, Freschi M, Gallus G, Rigatti P (1995) Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol 155(4):1227–1232CrossRef

Colombo R, Brausi M, Da Pozzo L, Salonia A, Montorsi F, Scattoni V, Roscigno M, Rigatti P (2001) Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication: a pilot study on marker lesion. Eur Urol J39(1):95–100CrossRef

Colombo R, Da Pozzo LF, Salonia A, Rigatti P, Leib Z, Baniel J, Caldarera E, Pavone-Macaluso M (2003) Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 21(23):4270–4276CrossRefPubMed

Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D (2011) Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int 107(6):912–918CrossRefPubMed

Deutsche Krebsgesellschaft (2015) Hyperthermie-Behandlung. http://www.krebsgesellschaft.de/onko-internetportal/basis-informationen-krebs/therapieformen/hyperthermie-behandlung.html . Zugegriffen: 16. Juni 2015

Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, Witjes JA, van der Heijden AG, Naspro R, Colombo R (2004) Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology 63(3):466–471CrossRefPubMed

Halachmi S, Moskovitz B, Maffezzini M, Conti G, Verweij F, Kedar D, Sandri SD, Nativ O, Colombo R (2011) Intravesical Mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. Urol Oncol 29(3):259–264. doi: 10.1016/j. urolonc.2009.02.012CrossRefPubMed

van der Heijden AG, Jansen CF, Verhaegh G, O’Donnell MA, Schalken JA, Witjes JA (2004a) The effect of hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines. Eur Urol 46(5):670–674CrossRef

van der Heijden AG, Kiemeney LA, Gofrit ON, Nativ O, Sidi A, Leib Z, Colombo R, Naspro R, Pavone M, Baniel J, Hasner F, Witjes JA (2004b) Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 46(1):65–71CrossRef

Herr HW (2000) Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol 163(1):60–61CrossRefPubMed

Herr HW, Sogani PC (2001) Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 166(4):1296–1299CrossRefPubMed

Herr HW, Pinsky CM, Whitmore WF Jr, Sogani PC, Oettgen HF, Melamed MR (1986) Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder. J Urol 135(2):265–167PubMed

Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BC, Abdel-Rahman S, Daugaard S, Salat C, Wendtner CM, Vujaskovic Z, Wessalowski R, Jauch KW, Dürr HR, Ploner F, Baur-Melnyk A, Mansmann U, Hiddemann W, Blay JY, Hohenberger P, European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-STBSG), European Society for Hyperthermic Oncology (ESHO) (2010) Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 11(6):561–570CrossRefPubMedPubMedCentral

Jakse G, Hall R, Bono A, Höltl W, Carpentier P, Spaander JP, van der Meijden AP, Sylvester R (2001) Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. Eur Urol 40(2):144–150CrossRefPubMed

Krege S, Giani G, Meyer R, Otto T, Rübben H (1996) A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. J Urol 156(3):962–966CrossRefPubMed

Lammers RJ, Witjes JA, Inman BA, Leibovitch I, Laufer M, Nativ O, Colombo R (2011) The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol 60(1):81–93CrossRefPubMed

Lüdecke G (2013) Urothelial cancer treatment: Intravesical approaches: organ preservation in high and extreme high risk non-muscle-invasive bladder cancer (NMIBC): outcome analysis of an interventional cohort study of the German Hyperthermia Chemotherapy Group in efficacy and side effects. (Posterpräsentation im Rahmen des 28. jährlichen Kongresses der Europäischen Gesellschaft für Urologie (EAU) am 18.03.2013 in Mailand, Italien)

Lüdecke G, Hasner F, Hanitsch H, Schmidt M, Schäfer L, Weidner W (2013) The German study group of intravesical hyperthermia-chemotherapy in non muscleinvasive bladder cancer presents their longterm results in efficacy and tolerability for optimized adjuvant therapy and bladder preservation. (Posterpräsentation im Rahmen des Jahreskongresses der GU ASCO Sektion am 14.02.2013 in Orlando, USA)

Moskovitz B, Meyer G, Kravtzov A, Gross M, Kastin A, Biton K, Nativ O (2005) Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. Ann Oncol 16(4):585–589CrossRefPubMed

Nativ O, Witjes JA, Hendricksen K, Cohen M, Kedar D, Sidi A, Colombo R, Leibovitch I (2009) Combined thermochemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol 182(4):1313–1317CrossRefPubMed

Paroni R, Salonia A, Lev A, Da Pozzo LF, Cighetti G, Montorsi F, Rigatti P, Colombo R (2001) Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol 52(3): 273–278CrossRefPubMedPubMedCentral

Rigatti P, Lev A, Colombo R (1991) Combined intravesical chemotherapy with mitomycin C and local bladder microwave-induced hyperthermia as a preoperative therapy for superficial bladder tumors: a preliminary clinical study. Eur Urol 20(3):204–210PubMed

Robert-Koch-Institut (RKI) (Hrsg) (2010) Verbreitung von Krebserkrankungen in Deutschland. Entwicklung der Prävalenzen in Deutschland zwischen 1990 und 2010. Beiträge zur Gesundheitsberichterstattung des Bundes. RKI, Berlin. http://www.rki.de/Krebs/SharedDocs/Downloads/Krebspraevalenz.pdf?blob=publicationFile. Zugegriffen: 14. April 2015

Svatek RS, Hollenbeck BK, Holmäng S, Lee R, Kim SP, Stenzl A, Lotan Y (2014) The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol 66(2):253–262CrossRefPubMed

Sylvester RJ, van der Meijden AP, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168(5):1964–1970CrossRefPubMed

Witjes J, Hendricksen K, Gofrit O, Risi O, Nativ O (2009) Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol 27(3):319–324CrossRef

Titel: Alternative Verfahren bei Urothelkarzinom
verfasst von: Priv.-Doz. Dr. med. C. Kempkensteffen
Prof. Dr. med. K. Miller
Prof. Dr. med. S. Höcht
Dr. med. M. Nausner
Priv.-Doz. Dr. med. F. Christoph
Verlag: Springer Berlin Heidelberg
Buch: Alternative operative Therapien in der Uroonkologie
Print ISBN: 978-3-662-44419-1

Electronic ISBN: 978-3-662-44420-7

Copyright-Jahr: 2016
DOI: https://doi.org/10.1007/978-3-662-44420-7_3

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen